Pharma startups like Pharnext are deploying machine learning to search for new therapeutic uses for “off patent” medications.
In the elegant quiet of the café at the Church of Sweden, a narrow Gothic-style building in Midtown Manhattan, Daniel Cohen is taking a break from explaining genetics. He moves toward the creaky piano positioned near the front door, sits down, and plays a flowing, flawless rendition of “Over the Rainbow.”
If human biology is the scientific equivalent of a complicated score, Cohen has learned how to navigate it like a virtuoso. Cohen was the driving force behind Généthon, the French laboratory that in December 1993 produced the first-ever “map” of the human genome. He essentially introduced Big Data and automation to the study of genomics, as he and his team demonstrated for the first time that it was possible to use super-fast computing to speed up the processing of DNA samples.
Scientists worldwide have built on Cohen’s insights, and Cohen himself, an MD with a Ph.D. in immunology, has gone on to success as a researcher and pharma executive. But a quarter-century later, genomics has yielded few of the kinds of paradigm-changing medical breakthroughs that many of its early innovators hoped for. Today, as chief executive and founder of Paris-based drug startup Pharnext, Cohen is striving to understand why that rainbow hasn’t led to a pot of gold.
“Any protein in the body has many different functions, not only one,” he says, returning from the piano to talk with me, “just as you are a person who has many functions in the population, not just one.” The phenomenon Cohen is describing is “pleiotropy,” the capacity of a single gene to have multiple, seemingly unrelated effects. It is one of the complexities of disease that has repeatedly frustrated medical researchers in their quest for therapies for the most stubborn illnesses.
Cohen not only appreciates pleiotropy’s significance: He believes that Pharnext and other drugmakers may soon exploit it—with a powerful boost from artificial intelligence. By embracing the body’s complexity, and by using A.I. to more methodically analyze and map the way the chain reactions of disease sweep through the body, he hopes to develop combinations of drugs tuned to attack a plethora of medical conditions.
Image Credit: Roberto Frankenberg
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
Particles that are mere nanometers in size are at the forefront of scientific research today. They come in many different shapes: rods, spheres, cubes, vesicles, S-shaped worms and even donut-like rings. What makes them [...]
Controlling the interactions between light and matter has been a long-standing ambition for scientists seeking to develop and advance numerous technologies that are fundamental to society. With the boom of nanotechnology in recent years, [...]
In her inaugural podcast, Jamilee interviews Frank Boehm of NanoApps Medical Inc and NanoApps Athletics Inc. From Jamilee's podcast: Welcome to the first episode of "In a Click". On todays show I chat with [...]
Frank Boehm (NanoApps Medical Inc. founder) and Amanda Scott (NA CEO) join NanoApps Athletics Inc. NanoApps Athletics Inc proposes a unique synergistic biochemical/nanomedical strategy for the expedited repair and healing of Achilles tendon micro [...]
In a paper published in Nature's NPJ Quantum Information ("Multiphoton quantum-state engineering using conditional measurements"), Omar Magaña-Loaiza, assistant professor in the Louisiana State University (LSU) Department of Physics & Astronomy, and his team of [...]
According to a report in the Financial Times, a team of researchers from Google led by John Martinis have demonstrated quantum supremacy for the first time. This is the point at which a quantum [...]
A new nanomaterial developed by scientists at the University of Bath could solve a conundrum faced by scientists probing some of the most promising types of future pharmaceuticals (Nanoscale Horizons, "Measuring optical [...]
Researchers at the Nanoscience Center and Faculty of Information Technology in the University of Jyväskylä, Finland, have achieved a significant step forward in predicting atomic structures of hybrid nanoparticles. A research article published in [...]
Nanomedical Device and Systems Design: Challenges, Possibilities, Visions now available to rent on Kindle
To accommodate students who wish to read the book at an affordable cost, Nanomedical Device and Systems Design: Challenges, Possibilities, Visions by Frank Boehm (CEO NanoApps Medical Inc.) is available to rent on Kindle. This book benefits [...]
Tools that detect cancer in its early stages can increase patient survival and quality of life. However, cancer screening approaches often call for expensive equipment and trips to the clinic, which may not be [...]
The blood-brain barrier is a physiological boundary layer that works highly selectively and thus protects the brain: On the one hand, pathogens or toxins are effectively prevented from penetrating the brain, on the other [...]